Literature DB >> 9332597

Persistent infections by Leishmania (Viannia) braziliensis.

J L Ramírez1, P Guevara.   

Abstract

Here we review the phenomenon of persistency in Leishmania (Viannia) braziliensis infections. In other Leishmania species where appropriate animal models exist, considerable advances in the understanding of basic immunologic mechanisms of persistency have been made; for a review see Aebisher (1994). On the contrary, the evidences of persistence in infections with L. braziliensis rest on studies of human clinical cases many of which we summarized and discussed in this work.

Entities:  

Mesh:

Year:  1997        PMID: 9332597     DOI: 10.1590/s0074-02761997000300006

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  15 in total

1.  Opsonization modulates Rac-1 activation during cell entry by Leishmania amazonensis.

Authors:  J Morehead; I Coppens; N W Andrews
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

2.  Toward a novel experimental model of infection to study American cutaneous leishmaniasis caused by Leishmania braziliensis.

Authors:  Tatiana R de Moura; Fernanda O Novais; Fabiano Oliveira; Jorge Clarêncio; Almério Noronha; Aldina Barral; Claudia Brodskyn; Camila I de Oliveira
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  T-bet, GATA-3, and Foxp3 expression and Th1/Th2 cytokine production in the clinical outcome of human infection with Leishmania (Viannia) species.

Authors:  Yira Rosalba Díaz; Ricardo Rojas; Liliana Valderrama; Nancy Gore Saravia
Journal:  J Infect Dis       Date:  2010-08-15       Impact factor: 5.226

4.  Dual Host-Intracellular Parasite Transcriptome of Enucleated Cells Hosting Leishmania amazonensis: Control of Half-Life of Host Cell Transcripts by the Parasite.

Authors:  Cristina M Orikaza; Carina C Pessoa; Fernanda V Paladino; Pilar T V Florentino; Clara L Barbiéri; Hiro Goto; Eduardo Milton Ramos-Sanchez; José Franco da Silveira; Michel Rabinovitch; Renato A Mortara; Fernando Real
Journal:  Infect Immun       Date:  2020-10-19       Impact factor: 3.441

5.  Evaluation of in vitro and in vivo Efficacy of a Novel Amphotericin B-Loaded Nanostructured Lipid Carrier in the Treatment of Leishmania braziliensis Infection.

Authors:  Jéssica Rebouças-Silva; Maraine Catarina Tadini; Danielle Devequi-Nunes; Ana Luíza Mansur; Paulo S Silveira-Mattos; Camila I de Oliveira; Fábio R Formiga; Andresa A Berretta; Franciane Marquele-Oliveira; Valéria M Borges
Journal:  Int J Nanomedicine       Date:  2020-11-05

6.  Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian Amazon.

Authors:  Jorge Augusto de Oliveira Guerra; Suzane Ribeiro Prestes; Henrique Silveira; Leila Inês de Aguiar Raposo Câmara Coelho; Pricila Gama; Aristoteles Moura; Valdir Amato; Maria das Graças Vale Barbosa; Luiz Carlos de Lima Ferreira
Journal:  PLoS Negl Trop Dis       Date:  2011-03-08

7.  The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure.

Authors:  Y Belkaid; K F Hoffmann; S Mendez; S Kamhawi; M C Udey; T A Wynn; D L Sacks
Journal:  J Exp Med       Date:  2001-11-19       Impact factor: 14.307

8.  Fibroblasts as host cells in latent leishmaniosis.

Authors:  C Bogdan; N Donhauser; R Döring; M Röllinghoff; A Diefenbach; M G Rittig
Journal:  J Exp Med       Date:  2000-06-19       Impact factor: 14.307

9.  Occupationally acquired american cutaneous leishmaniasis.

Authors:  Maria Edileuza Felinto de Brito; Maria Sandra Andrade; Ericka Lima de Almeida; Angela Cristina Rapela Medeiros; Roberto Pereira Werkhäuser; Ana Isabele Freitas de Araújo; Sinval Pinto Brandão-Filho; Alzira Maria Paiva de Almeida; Eduardo Henrique Gomes Rodrigues
Journal:  Case Rep Dermatol Med       Date:  2012-11-28

10.  Role for CD4(+) CD25(+) regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity.

Authors:  Susana Mendez; Stacie K Reckling; Ciriacco A Piccirillo; David Sacks; Yasmine Belkaid
Journal:  J Exp Med       Date:  2004-07-19       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.